Buyout on Horizon: Amgen floats $28B offer for rare disease drug maker as Sanofi exits bidding war

It’s official: Just weeks after rare disease drug maker Horizon Therapeutics revealed it was at the heart of a bidding war between Amgen, Johnson & Johnson and Sanofi, Big Biotech Amgen has emerged with a multibillion-dollar M&A victory.